Breaking News Instant updates and real-time market news.

VRX

Valeant

$15.76

-1.4001 (-8.16%)

, TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.97

-0.035 (-0.17%)

12:29
11/30/16
11/30
12:29
11/30/16
12:29

Paulson opposed Valeant sale of Salix, deal now 'all but dead,' CNBC says

Valeant's (VRX) potential deal to sell its Salix business to Japan's Takeda Pharma (TKPYY) is "all but dead," reports CNBC's Scott Wapner, citing sources. Price disagreements emerged at the eleventh hour, as Takeda wanted to cut the deal's royalty payments in half, sources told Wapner, adding that Valeant "didn't really want to sell in the first place." Wapner's sources also told him that John Paulson, one of the largest investors in Valeant, was against the deal, saying it would cut future growth prospects.

VRX

Valeant

$15.76

-1.4001 (-8.16%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.97

-0.035 (-0.17%)

  • 13

    Dec

  • 14

    Dec

  • 16

    Feb

VRX Valeant
$15.76

-1.4001 (-8.16%)

11/18/16
DBAB
11/18/16
NO CHANGE
Target $24
DBAB
Hold
Deutsche still likes near-term setup for Valeant shares
Deutsche Bank analyst Gregg Gilbert said yesterday that he still likes the near-term setup for shares of Valeant Pharmaceuticals after federal prosecutors announced criminal charges against former executive Gary Tanner and the former CEO of Philidor. It is "good to see" that Valeant and other senior executives were not charged, Gilbert told investors in a research note. The charges could be an important step forward as the company and new management team distance themselves from the past, Gilbert wrote. The analyst points out that the bar for 2016 has already been lowered and that new CFO Paul Herendeen thinks of guidance as a commitment. Gilbert keeps a Hold rating on Valeant with a $24 price target. The stock closed yesterday up 12c to $17.98.
11/18/16
ADAM
11/18/16
NO CHANGE
Target $17
ADAM
Hold
Valeant negative headlines remain a risk, says Canaccord
Canaccord analyst Neil Maruoka noted yesterday's headlines regarding criminal charges against a former Valeant executive. He said although the charges are not pertinent to Valeant it underscores the negative headline risk that is associated with owning the shares. Maruoka said the company's lower guidance suggests growth headwinds into next year and believes the company still needs to sell assets to de-lever. Maruoka maintained his Hold rating and $17 price target on Valeant shares.
11/23/16
MZHO
11/23/16
DOWNGRADE
Target $11
MZHO
Underperform
Valeant downgraded to Underperform from Neutral at Mizuho
Mizuho analyst Irina Koffler downgraded Valeant Pharmaceuticals to Underperform, her firm's sell rating equivalent, and cut her price target for the shares to $11 from $25. The drugmaker closed yesterday at $17.83. Koffler believes growth challenges, 2017 guidance risk, legal overhangs and weaker asset divestitures create an unfavorable risk/reward profile. She expects the shares to trend lower over the next 6-12 months.
11/29/16
DBAB
11/29/16
NO CHANGE
Target $24
DBAB
Hold
Deutsche weighs impact on Valeant should Salix be sold
Deutsche Bank analyst Gregg Gilbert hopes to hear closure soon on a potential sale of Salix by Valeant Pharmaceuticals. While a sale is not a "no-brainer" given the unit's growth and durability, a deal could improve Valeant's debt situation and add to its value, Gilbert tells investors in a research note. His preliminary analysis suggests that a sale of Salix for $10B coupled with de-levering would be "significantly" dilutive to earnings but accretive to Valeant's value. His analysis yields earnings dilution of 26%-27% in 2018- 2021 and an increase in the company's theoretical discounted cash flow value to $32 from $24. Gilbert continues to like the near-term setup in shares of Valeant but keeps a Hold rating on the shares with a $24 price target. The pharmaceutical closed yesterday up 44c to $17.44.
TKPYY Takeda Pharmaceutical Co. Ltd.
$20.97

-0.035 (-0.17%)

06/08/16
RHCO
06/08/16
NO CHANGE
RHCO
Ultragenyx collaboration with Takeda 'exceptionally positive,' says SunTrust
After Ultragenyx (RARE) announced a development and commercialization collaboration for rare genetic diseases with Takeda (TKPYY), SunTrust says the deal terms are "exceptionally positive" for Ultragenyx. The firm notes that the latter company will receive both compounds and cash payments from Takeda, while Takeda will only get comemrcial rights in Asia. The firm keeps a Buy rating on Ultragenyx.
07/07/16
UBSW
07/07/16
INITIATION
UBSW
Neutral
Takeda Pharmaceutical initiated with a Neutral at UBS
UBS analyst Atsushi Seki started Takeda with a Neutral rating and Y4,600 price target.
09/14/16
SBSH
09/14/16
NO CHANGE
Target $4
SBSH
Neutral
Citi views Synergy Pharmaceuticals as potential target for Takeda
Citi analyst Liav Abraham calls Synergy Pharmaceuticals (SGYP) the most likely potential target for Takeda Pharmaceutical (TKPYY) among her coverage universe. The Financial Times earlier today reported that Takeda is ready to spend as much as $15B in acquisitions to expand its business in the United States. Abraham has a Neutral rating on Synergy with a $4 price target. The analyst sees Synergy as a potential target given the "extensive resources" needed to commercialize its lead asset, plecanatide, as well as Takdea's presence in the irritable bowel syndrome/chronic idiopathic constipation space. Shares of Synergy are up 6% to $5.18 in early trading.
09/15/16
WELS
09/15/16
NO CHANGE
WELS
Street underestimating potential of PRA Health deal, says Wells Fargo
Wells Fargo believes that the Street is underestimating the potential benefit to PRA Health (PRAH) of its deal with Takeda (TKPYY). The firm expects PRA's bookings over the next year to significantly exceed the industry average, causing 2017 and 2018 consensus estimates for the company to rise. Wells raised its price target on PRA to $65-$67 from $56-$59 and keeps an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

PES

Pioneer Energy

$6.70

0.45 (7.20%)

05:31
12/07/16
12/07
05:31
12/07/16
05:31
Syndicate
Pioneer Energy 10.5M share Spot Secondary priced at $5.75 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SLM

Sallie Mae

$10.78

0.23 (2.18%)

05:30
12/07/16
12/07
05:30
12/07/16
05:30
Initiation
Sallie Mae initiated  »

Sallie Mae initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIK

Michaels

$23.85

-0.46 (-1.89%)

05:29
12/07/16
12/07
05:29
12/07/16
05:29
Downgrade
Michaels rating change  »

Michaels downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

K

Kellogg

$71.97

0.3 (0.42%)

05:28
12/07/16
12/07
05:28
12/07/16
05:28
Downgrade
Kellogg rating change  »

Kellogg downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAVI

Navient

$17.03

0.03 (0.18%)

05:28
12/07/16
12/07
05:28
12/07/16
05:28
Initiation
Navient initiated  »

Navient initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRSK

Verisk Analytics

$83.04

0.13 (0.16%)

05:25
12/07/16
12/07
05:25
12/07/16
05:25
Initiation
Verisk Analytics initiated  »

Verisk Analytics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

CMCO

Columbus McKinnon

$27.59

1.07 (4.03%)

05:25
12/07/16
12/07
05:25
12/07/16
05:25
Hot Stocks
Columbus McKinnon to acquire STAHL CraneSystems for about $240M »

Columbus McKinnon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLGX

CoreLogic

$37.89

-0.28 (-0.73%)

05:24
12/07/16
12/07
05:24
12/07/16
05:24
Initiation
CoreLogic initiated  »

CoreLogic initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

MGP

MGM Growth

$24.60

-0.18 (-0.73%)

, GLPI

Gaming and Leisure Properties

$30.70

0.24 (0.79%)

05:21
12/07/16
12/07
05:21
12/07/16
05:21
Downgrade
MGM Growth, Gaming and Leisure Properties, Boyd Gaming rating change  »

MGM Growth downgraded to…

MGP

MGM Growth

$24.60

-0.18 (-0.73%)

GLPI

Gaming and Leisure Properties

$30.70

0.24 (0.79%)

BYD

Boyd Gaming

$19.63

0.39 (2.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASX

Advanced Semiconductor

$5.38

0.11 (2.09%)

05:20
12/07/16
12/07
05:20
12/07/16
05:20
Hot Stocks
Advanced Semiconductor reports Nov. revenue up 1.3% to $821M »

Reports November ATM net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACIA

Acacia Communications

$70.14

1.08 (1.56%)

05:19
12/07/16
12/07
05:19
12/07/16
05:19
Hot Stocks
Acacia Communications establishes EMEA-APAC headquarters in Limerick, Ireland »

Acacia Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$68.96

-0.01 (-0.01%)

05:18
12/07/16
12/07
05:18
12/07/16
05:18
Hot Stocks
Novartis drug Lucentis receives EU approval in new indication »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WDC

Western Digital

$63.85

1.76 (2.83%)

05:18
12/07/16
12/07
05:18
12/07/16
05:18
Recommendations
Western Digital analyst commentary  »

Western Digital price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$12.56

0.12 (0.96%)

05:16
12/07/16
12/07
05:16
12/07/16
05:16
Hot Stocks
Ford reports Nov. China sales up 17% to 124,113 vehicles »

Ford and its joint…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

  • 10

    Jan

MU

Micron

$19.06

0.45 (2.42%)

05:15
12/07/16
12/07
05:15
12/07/16
05:15
Initiation
Micron initiated  »

Micron initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 21

    Dec

ESGR

Enstar Group

$194.15

0.5 (0.26%)

05:12
12/07/16
12/07
05:12
12/07/16
05:12
Hot Stocks
Enstar Group announces reinsurance of QBE Legacy U.S. business »

Enstar Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRUE

TrueCar

$12.44

0.02 (0.16%)

05:10
12/07/16
12/07
05:10
12/07/16
05:10
Recommendations
TrueCar analyst commentary  »

TrueCar price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWI

Titan International

$11.68

0.08 (0.69%)

05:10
12/07/16
12/07
05:10
12/07/16
05:10
Hot Stocks
Titan International appoints interim CFO James Froisland to CFO »

The board of Titan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANET

Arista Networks

$93.86

1.11 (1.20%)

, HPE

HP Enterprise

$23.96

-0.25 (-1.03%)

05:08
12/07/16
12/07
05:08
12/07/16
05:08
Recommendations
Arista Networks, HP Enterprise analyst commentary  »

Arista Networks price…

ANET

Arista Networks

$93.86

1.11 (1.20%)

HPE

HP Enterprise

$23.96

-0.25 (-1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

DPSGY

Deutsche Post

$31.62

0.015 (0.05%)

05:03
12/07/16
12/07
05:03
12/07/16
05:03
Upgrade
Deutsche Post rating change  »

Deutsche Post upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLLLY

Delta Lloyd

05:03
12/07/16
12/07
05:03
12/07/16
05:03
Upgrade
Delta Lloyd rating change  »

Delta Lloyd upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSREY

Swiss Re

$23.68

0.195 (0.83%)

05:02
12/07/16
12/07
05:02
12/07/16
05:02
Upgrade
Swiss Re rating change  »

Swiss Re upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZURVY

Zurich Insurance

$26.82

0.365 (1.38%)

05:01
12/07/16
12/07
05:01
12/07/16
05:01
Upgrade
Zurich Insurance rating change  »

Zurich Insurance upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AV

Aviva

$11.86

0.36 (3.13%)

05:00
12/07/16
12/07
05:00
12/07/16
05:00
Upgrade
Aviva rating change  »

Aviva upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHP

BHP Billiton

$38.34

-0.4 (-1.03%)

04:58
12/07/16
12/07
04:58
12/07/16
04:58
Downgrade
BHP Billiton rating change  »

BHP Billiton downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.